Boldenone and MK-2866 Interaction

Monitor
Mechanism-based 55% confidence

Boldenone and MK-2866 have an interaction requiring monitoring for interaction with 55% confidence. Both Boldenone and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

Boldenone

Anabolic-Androgenic Steroid | Lean Mass & Vascularity

Boldenone exerts its anabolic effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and increased IGF-1 output in muscle tissue. The 1,2-double bond modification reduces the compound's affinity for 5-alpha reductase, meaning boldenone is not efficiently converted to a more potent dihydro-metabolite in the way testosterone is converted to DHT.

Half-life: ~14 days (undecylenate) Typical dose: 200-400 mg/week (moderate) anabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgenicaromatase inhibitorblood pressure raisingcarcinogenic risk
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 androgenic compounds (Boldenone, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (Boldenone, MK-2866). Monitor accordingly.
2x 2 HPTA-suppressive compounds (Boldenone, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Boldenone, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Boldenone with MK-2866?

Yes, but with caution. Both Boldenone and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is Boldenone and MK-2866 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, carcinogenic risk, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between Boldenone and MK-2866?

Both Boldenone and MK-2866 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.

How should I time Boldenone and MK-2866?

Boldenone has a half-life of ~14 days (undecylenate) and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Boldenone vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.